These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 17107908)

  • 1. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
    Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
    PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orbital plasmablastic lymphoma with remission following chemotherapy.
    Degnan AJ; Levy LM
    J Radiol Case Rep; 2011; 5(2):1-7. PubMed ID: 22470775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
    Petru E; Singer CF; Polterauer S; Galid A; Schauer C; Klocker J; Seifert M; Reinthaller A; Benedicic C; Hubalek M; Hefler L; Marth C; Scholl-Firon T; Bogner G; Zeimet AG
    Wien Med Wochenschr; 2015 Oct; 165(19-20):387-94. PubMed ID: 26471371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.
    Xu H; Gong Q; Vogl FD; Reiner M; Page JH
    Support Care Cancer; 2016 Feb; 24(2):723-730. PubMed ID: 26162536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.
    Kam G; Yiu R; Loh Y; Ang AL; Yueh LL; Goh YT; Wong GC
    Support Care Cancer; 2015 Mar; 23(3):643-9. PubMed ID: 25160495
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.
    Yu XQ; Chen WH; O'Connell DL
    BMC Cancer; 2010 May; 10():231. PubMed ID: 20497580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
    Aapro M; Crawford J; Kamioner D
    Support Care Cancer; 2010 May; 18(5):529-41. PubMed ID: 20191292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
    Carrato A; Paz-Ares Rodríguez L; Rodríguez Lescure A; Casas Fernández de Tejerina AM; Díaz Rubio García E; Pérez Segura P; Constenla Figueiras M; García Carbonero R; Gómez Codina J; Lluch Hernández A; Maroto Rey JP; Martín Jiménez M; Mayordomo Cámara JI; Moreno Nogueira JA; Rueda Domínguez A;
    Clin Transl Oncol; 2009 Jul; 11(7):446-54. PubMed ID: 19574202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
    Sierra J; Szer J; Kassis J; Herrmann R; Lazzarino M; Thomas X; Noga SJ; Baker N; Dansey R; Bosi A
    BMC Cancer; 2008 Jul; 8():195. PubMed ID: 18616811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
    Gregory SA; Trümper L
    Ann Oncol; 2005 Sep; 16(9):1413-24. PubMed ID: 15932900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma.
    Wolf M; Bentley M; Marlton P; Horvath N; Lewis ID; Spencer A; Herrmann R; Arthur C; Durrant S; van Kerkhoven M; MacMillan J; Mrongovius R
    Leuk Lymphoma; 2006 Nov; 47(11):2344-50. PubMed ID: 17107908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
    Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
    Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
    Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.